These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 134998)

  • 1. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.
    Moroi M; Aoki N
    J Biol Chem; 1976 Oct; 251(19):5956-65. PubMed ID: 134998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The primary inhibitor of plasmin in human plasma.
    Müllertz S; Clemmensen I
    Biochem J; 1976 Dec; 159(3):545-53. PubMed ID: 137718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.
    Collen D
    Eur J Biochem; 1976 Oct; 69(1):209-16. PubMed ID: 136345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
    Müllertz S
    Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of alpha2-plasmin inhibitor on fibrin clot lysis. Its comparison with alpha2-macroglobulin.
    Aoki N; Moroi M; Tachiya K
    Thromb Haemost; 1978 Feb; 39(1):22-31. PubMed ID: 77050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the interaction of alpha2-plasmin inhibitor and proteases. Evidence for the formation of a covalent crosslinkage and non-covalent weak bondings between the inhibitor and proteases.
    Moroi M; Aoki N
    Biochim Biophys Acta; 1977 Jun; 482(2):412-20. PubMed ID: 141946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
    Harpel PC
    J Clin Invest; 1981 Jul; 68(1):46-55. PubMed ID: 6166634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum inhibitors in fibrinolysis.
    Gallimore MJ
    Br J Haematol; 1975 Oct; 31(2):217-31. PubMed ID: 53065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.
    Harpel PC; Chang TS; Verderber E
    J Biol Chem; 1985 Apr; 260(7):4432-40. PubMed ID: 3156857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inhibitor of plasminogen activation from human placenta. Purification and characterization.
    Wun TC; Reich E
    J Biol Chem; 1987 Mar; 262(8):3646-53. PubMed ID: 3102492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma.
    Stump DC; Thienpont M; Collen D
    J Biol Chem; 1986 Sep; 261(27):12759-66. PubMed ID: 3091604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of a slow and tight-binding inhibitor of plasmin isolated from Russell's viper venom.
    Cheng AC; Tsai IH
    Biochim Biophys Acta; 2014 Jan; 1840(1):153-9. PubMed ID: 23999090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent molecular weight approximately 92 000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domains.
    Robbins KC; Tanaka Y
    Biochemistry; 1986 Jun; 25(12):3603-11. PubMed ID: 2941075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
    Thorsen S; Müllertz S; Suenson E; Kok P
    Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial purification and characterization of a new fast-acting plasmin inhibitor from human platelets. Evidence for non-identity with the known plasma proteinase inhibitors.
    Sandbjerg Hansen M; Clemmensen I
    Biochem J; 1980 Apr; 187(1):173-80. PubMed ID: 6447502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the murine plasma fibrinolytic system.
    Lijnen HR; van Hoef B; Beelen V; Collen D
    Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
    Lijnen HR; Van Hoef B; Collen D
    Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of activation of rabbit plasminogen by urokinase.
    Sodetz JM; Castellino FJ
    J Biol Chem; 1975 Apr; 250(8):3041-9. PubMed ID: 123529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
    Müllertz S; Thorsen S; Sottrup-Jensen L
    Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.